MX355408B - Inhibidores a base de oligonucleotidos que comprenden un motivo de acido nucleico bloqueado. - Google Patents

Inhibidores a base de oligonucleotidos que comprenden un motivo de acido nucleico bloqueado.

Info

Publication number
MX355408B
MX355408B MX2014015643A MX2014015643A MX355408B MX 355408 B MX355408 B MX 355408B MX 2014015643 A MX2014015643 A MX 2014015643A MX 2014015643 A MX2014015643 A MX 2014015643A MX 355408 B MX355408 B MX 355408B
Authority
MX
Mexico
Prior art keywords
oligonucleotides
chemically modified
oligonucleotide
locked nucleic
nucleic acid
Prior art date
Application number
MX2014015643A
Other languages
English (en)
Other versions
MX2014015643A (es
Inventor
Van Rooij Eva
M Dalby Christina
L Montgomery Rusty
Original Assignee
Miragen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Miragen Therapeutics Inc filed Critical Miragen Therapeutics Inc
Publication of MX2014015643A publication Critical patent/MX2014015643A/es
Publication of MX355408B publication Critical patent/MX355408B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/343—Spatial arrangement of the modifications having patterns, e.g. ==--==--==--
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a de modificación química para oliqonucleótidos. Los oligonucleótidos de la presente invención, tales como los oligonucleótidos anti-sentido modificados químicamente, pueden tener eficacia aumentada in vivo. Los oligonucleótidos modificados químicamente proporcionan ventajas en uno o más de potencia, eficacia de suministro, especificidad, toxicidad y/o estabilidad blanco. Los oliqonucleótidos modificados químicamente tienen un motivo o patrón de modificación química específica de ácidos nucleicos bloqueados (LNA). El oligonucleótido (por ejemplo el oligonucleótido anti-sentido) puede dirigirse a un ARN, tal como miARN o mARN. También se proporcionan en la presente composiciones que comprenden los oligonucleótidos modificados químicamente y los métodos para utilizar los oligonucleótidos modificados químicamente como terapéuticos para diversos trastornos, entre los que se incluyen trastornos cardiovasculares.
MX2014015643A 2012-06-21 2013-06-21 Inhibidores a base de oligonucleotidos que comprenden un motivo de acido nucleico bloqueado. MX355408B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261662746P 2012-06-21 2012-06-21
US201361801533P 2013-03-15 2013-03-15
PCT/US2013/047157 WO2013192576A2 (en) 2012-06-21 2013-06-21 Oligonucleotide-based inhibitors comprising locked nucleic acid motif

Publications (2)

Publication Number Publication Date
MX2014015643A MX2014015643A (es) 2015-07-17
MX355408B true MX355408B (es) 2018-04-18

Family

ID=49769732

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014015643A MX355408B (es) 2012-06-21 2013-06-21 Inhibidores a base de oligonucleotidos que comprenden un motivo de acido nucleico bloqueado.

Country Status (12)

Country Link
US (3) US9388408B2 (es)
EP (2) EP3354734B1 (es)
JP (2) JP6208228B2 (es)
KR (1) KR101928418B1 (es)
CN (2) CN104685056A (es)
AU (1) AU2013278011B2 (es)
CA (1) CA2876180C (es)
DK (1) DK3354734T3 (es)
ES (1) ES2801875T3 (es)
HK (2) HK1209781A1 (es)
MX (1) MX355408B (es)
WO (1) WO2013192576A2 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2817371A1 (en) * 2010-12-15 2012-06-21 Miragen Therapeutics Microrna inhibitors comprising locked nucleotides
DK2702155T3 (en) 2011-04-25 2017-05-01 Regulus Therapeutics Inc MICRO-RNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY
NZ630591A (en) 2012-04-25 2017-02-24 Regulus Therapeutics Inc Microrna compounds and methods for modulating mir-21 activity
CN104685056A (zh) 2012-06-21 2015-06-03 米拉根医疗股份有限公司 包含锁核酸基序的基于寡核苷酸的抑制剂
UA116639C2 (uk) 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта
EP2757157A1 (en) * 2013-01-17 2014-07-23 Ecole Polytechnique Federale de Lausanne (EPFL) Modulation of mitophagy and use thereof
JP6410791B2 (ja) 2013-03-15 2018-10-24 ミラゲン セラピューティクス， インコーポレイテッド Ｍｉｒ−１４５のロックト核酸阻害剤およびその使用
SG10201803157XA (en) 2013-05-01 2018-05-30 Regulus Therapeutics Inc Microrna compounds and methods for modulating mir-122
WO2016022536A2 (en) 2014-08-04 2016-02-11 MiRagen Therapeutics, Inc. Inhibitors of myh7b and uses thereof
BR112017001931A2 (pt) 2014-08-07 2017-11-28 Regulus Therapeutics Inc direcionamento de micrornas para distúrbios metabólicos
WO2016069717A1 (en) * 2014-10-28 2016-05-06 MiRagen Therapeutics, Inc. Inhibitors of mirnas in regulation of arterial stiffness and uses thereof
HK1249108A1 (zh) * 2015-01-20 2018-10-26 米拉根医疗股份有限公司 Mir-92抑制剂及其用途
US10538769B2 (en) 2015-09-04 2020-01-21 Oregon State University Renal selective inhibition of cytochrome P450 3A5
AU2016326548A1 (en) * 2015-09-22 2018-03-29 MiRagen Therapeutics, Inc. miR-19 modulators and uses thereof
CA3001723A1 (en) * 2015-10-15 2017-04-20 City Of Hope Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof
WO2017087486A1 (en) * 2015-11-16 2017-05-26 Ohio State Innovation Foundation Methods and compositions for treating disorders and diseases using survival motor neuron (smn) protein
CN105435247A (zh) * 2015-12-31 2016-03-30 中国医学科学院基础医学研究所 miR-378在预防和/或治疗肥胖症中的用途
WO2017187426A1 (en) 2016-04-29 2017-11-02 Aptamir Therapeutics, Inc. Inhibition of mir-22 mirna by apt-110
CN106011140B (zh) * 2016-06-06 2018-12-18 同济大学 反义microRNA-25及其应用
WO2017214953A1 (zh) * 2016-06-16 2017-12-21 毛侃琅 一种特异抑制人 miRNA-424 表达的慢病毒载体的构建及其应用
WO2017214952A1 (zh) * 2016-06-16 2017-12-21 毛侃琅 特异抑制人 miRNA-185 表达的慢病毒载体的构建及其应用
WO2017219165A1 (zh) * 2016-06-19 2017-12-28 毛侃琅 特异敲低人 miRNA-29a 和 miR-140 表达的慢病毒载体及其应用
WO2017219166A1 (zh) * 2016-06-19 2017-12-28 毛侃琅 一种同时抑制双 miRNA 表达的慢病毒载体及其应用
WO2017219170A1 (zh) * 2016-06-19 2017-12-28 毛侃琅 特异抑制人 miRNA-29a 和 miR-424 表达的慢病毒载体的构建及其应用
US20200276220A1 (en) * 2016-07-07 2020-09-03 MiRagen Therapeutics, Inc. Methods for treating cutaneous t-cell lymphoma (ctcl) with mir-155 inhibitors
ES3014985T3 (en) 2016-08-12 2025-04-28 Immunowork Llc Diagnosis, prevention, and/or treatment of autoimmune diseases
AU2017368050A1 (en) 2016-11-29 2019-06-20 Puretech Lyt, Inc. Exosomes for delivery of therapeutic agents
EP3601565A4 (en) * 2017-03-25 2021-01-06 Miragen Therapeutics, Inc. MIR-92 INHIBITORS IN THE TREATMENT OF HEART FAILURE
CN110141577A (zh) * 2018-02-13 2019-08-20 上海三炬生物科技有限公司 miRNA-24-3p核苷酸类似物在制备药物中的应用
WO2019178411A1 (en) * 2018-03-14 2019-09-19 Beth Israel Deaconess Medical Center Inhibitors of micro-rna 22
JP7279081B2 (ja) 2018-05-08 2023-05-22 レグルス セラピューティクス インコーポレイテッド Ｍｉｒ－１２２を調節するためのマイクロｒｎａ化合物及び方法
WO2020051398A1 (en) * 2018-09-06 2020-03-12 Aptamir Therapeutics, Inc. Metabolic benefits of short mir-22 mirna antagomir therapies
CN110358769A (zh) * 2019-07-30 2019-10-22 中国医学科学院血液病医院(中国医学科学院血液学研究所) 经锁核酸和硫代磷酸修饰的miRNA类似物及其在制备抗肿瘤药物中的应用
CN110433170B (zh) * 2019-07-31 2021-04-27 南京医科大学 心脏抽吸液miR-28-5p在心脏疾病中的应用
IT201900017234A1 (it) * 2019-09-25 2021-03-25 Int Centre For Genetic Engineering And Biotechnology Anti-miRNA per il trattamento del leiomioma
WO2021097390A1 (en) * 2019-11-15 2021-05-20 Duke University Cellular molecular theranostics nanoprobe systems and methods
CN111118008B (zh) * 2020-01-16 2023-08-22 南京医科大学 Mcl1基因的3’-UTR序列及其应用
CA3174443A1 (en) * 2020-03-04 2021-09-10 The Trustees Of Indiana University Methods to re-engage a fetal wound healing pathway for adult skin repair
US20230265426A1 (en) * 2020-07-23 2023-08-24 Johann Wolfgang Goethe-Universität Frankfurt Combinatorial inhibition of mirnas for treatment of heart failure
WO2022154636A1 (ko) * 2021-01-18 2022-07-21 (주)스템메디텍 Mir 145 억제제를 유효성분으로 포함하는 심근경색증의 치료용 조성물
EP4662317A1 (en) 2023-02-07 2025-12-17 Universitetet i Tromsø - Norges Arktiske Universitet Pharmaceutical composition for use in treatment of venous thromboembolism
GB202305535D0 (en) 2023-04-14 2023-05-31 Imperial College Innovations Ltd Oligonucleotide decoy
WO2025008641A2 (en) * 2023-07-06 2025-01-09 Imperial College Innovations Limited Rna molecule
WO2025104709A1 (en) * 2023-11-17 2025-05-22 Biorchestra Co., Ltd. Microrna-378a-3p antisense oligonucleotides and uses thereof

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981505A (en) 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
WO1995003843A1 (en) 1993-07-30 1995-02-09 The Regents Of The University Of California Endocardial infusion catheter
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US5840710A (en) 1994-12-09 1998-11-24 Genzyme Corporation Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules
US6770748B2 (en) 1997-03-07 2004-08-03 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogue
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6416510B1 (en) 1997-03-13 2002-07-09 Biocardia, Inc. Drug delivery catheters that attach to tissue and methods for their use
US6217900B1 (en) 1997-04-30 2001-04-17 American Home Products Corporation Vesicular complexes and methods of making and using the same
JP2002510319A (ja) 1997-07-01 2002-04-02 アイシス・ファーマシューティカルス・インコーポレーテッド オリゴヌクレオチドの消化管を介したデリバリーのための組成物及び方法
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US6749617B1 (en) 1997-11-04 2004-06-15 Scimed Life Systems, Inc. Catheter and implants for the delivery of therapeutic agents to tissues
US6833361B2 (en) 1998-05-26 2004-12-21 Ribapharm, Inc. Nucleosides having bicyclic sugar moiety
CN1311630A (zh) 1998-05-26 2001-09-05 Icn药品公司 具有双环糖部分的新核苷类
DE60045706D1 (de) 1999-03-18 2011-04-21 Exiqon As Detektion von genmutationen mittels lna primer
AU7406600A (en) * 1999-10-04 2001-05-10 Exiqon A/S A method of increasing the specificity of oxy-lna oligonucleotides
JP4413493B2 (ja) 2000-10-04 2010-02-10 サンタリス ファーマ アー／エス プリンｌｎａ類似体の改善された合成方法
IL161100A0 (en) 2001-09-28 2004-08-31 Max Planck Gesellschaft Identification of novel genes coding for small temporal rnas
JP4868739B2 (ja) 2002-05-06 2012-02-01 アルナイラム ファーマシューティカルズ， インコーポレイテッド 核酸の送達法
US20080214437A1 (en) 2002-09-06 2008-09-04 Mohapatra Shyam S Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
DK2284269T3 (en) 2002-11-18 2017-10-23 Roche Innovation Ct Copenhagen As Antisense design
DK1606406T4 (da) * 2003-03-21 2013-12-16 Santaris Pharma As Short Interfering RNA (siRNA) Analogues
EP1648914A4 (en) 2003-07-31 2009-12-16 Regulus Therapeutics Inc OLIGOMERIC COMPOUNDS AND COMPOSITIONS USEFUL FOR MODULATING SMALL NON-CODING RNA
WO2005017145A1 (ja) 2003-08-13 2005-02-24 Japan Biological Informatics Consortium 機能性ｒｎａが制御する被制御遺伝子の同定・予測方法及びその利用方法
JP5654722B2 (ja) 2003-11-26 2015-01-14 ユニバーシティ オブ マサチューセッツ 短鎖ｒｎａ機能の配列特異的阻害法
US20050256072A1 (en) 2004-02-09 2005-11-17 University Of Massachusetts Dual functional oligonucleotides for use in repressing mutant gene expression
EP2295604B1 (en) 2004-02-09 2015-04-08 Thomas Jefferson University Diagnosis and treatment of cancers with microRNA located in or near cancer-associated chromosomal features
AU2005214904B2 (en) 2004-02-13 2011-07-21 Rockefeller University Anti-microRNA oligonucleotide molecules
US20070203445A1 (en) 2004-02-26 2007-08-30 V-Kardia Pty Ltd Isolating cardiac circulation
AU2005216564A1 (en) 2004-02-26 2005-09-09 Osprey Medical Inc. Isolating cardiac circulation
US7722596B2 (en) 2004-02-26 2010-05-25 Osprey Medical, Inc. Regional cardiac tissue treatment
AU2005250432B2 (en) 2004-05-28 2011-09-15 Asuragen, Inc. Methods and compositions involving microRNA
CA2857881A1 (en) 2004-11-12 2006-12-28 Asuragen, Inc. Methods and compositions involving mirna and mirna inhibitor molecules
WO2006063356A1 (en) 2004-12-10 2006-06-15 Isis Phamaceuticals, Inc. Regulation of epigenetic control of gene expression
US20060185027A1 (en) 2004-12-23 2006-08-17 David Bartel Systems and methods for identifying miRNA targets and for altering miRNA and target expression
EP1959012A3 (en) 2004-12-29 2009-12-30 Exiqon A/S Novel oligonucleotide compositions and probe sequences useful for detection and analysis of microRNAs and their target mRNAs
US8071306B2 (en) 2005-01-25 2011-12-06 Merck Sharp & Dohme Corp. Methods for quantitating small RNA molecules
US7404969B2 (en) 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
WO2006089340A2 (en) 2005-02-23 2006-08-31 V-Kardia Pty Ltd Polynucleotide delivery to cardiac tissue
US20070065840A1 (en) 2005-03-23 2007-03-22 Irena Naguibneva Novel oligonucleotide compositions and probe sequences useful for detection and analysis of microRNAS and their target mRNAS
US9085774B2 (en) 2005-04-19 2015-07-21 Basf Plant Science Gmbh Methods controlling gene expression
SI2002003T1 (sl) 2005-05-27 2016-05-31 Ospedale San Raffaele S.R.L. Genski vektor, ki vsebuje mi-RNA
AU2006326517B2 (en) 2005-12-12 2013-02-21 The University Of North Carolina At Chapel Hill MicroRNAs that regulate muscle cell proliferation and differentiation
EP1966390A1 (en) 2005-12-29 2008-09-10 Exiqon A/S Detection of tissue origin of cancer
JP5213723B2 (ja) 2006-01-27 2013-06-19 アイシス ファーマシューティカルズ， インコーポレーテッド マイクロｒｎａの調節に使用するためのオリゴマー化合物及び組成物
MX2008012219A (es) 2006-04-03 2008-10-02 Santaris Pharma As Composicion farmaceutica que comprende oligonucleotidos antisentido anti-miarn.
US8466117B2 (en) 2006-07-28 2013-06-18 The Johns Hopkins University Compositions and methods for modulating angiogenesis
KR101485495B1 (ko) 2006-08-01 2015-01-22 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 베타-마이오신 중사슬의 발현을 활성화하는 마이크로-ｒｎａ의 동정
US20090306181A1 (en) 2006-09-29 2009-12-10 Children's Medical Center Corporation Compositions and methods for evaluating and treating heart failure
US8906870B2 (en) 2006-10-09 2014-12-09 Julius-Maximilians-Universitaet Wuerzberg MicroRNA (miRNA) for the diagnosis and treatment of heart diseases
WO2008147430A2 (en) 2006-10-11 2008-12-04 Nucleonics, Inc. Microrna-formatted multitarget interfering rna vector constructs and methods of using the same
CA2681568C (en) 2006-11-23 2019-01-08 Querdenker Aps Oligonucleotides for modulating target rna activity
EA200900782A1 (ru) 2006-12-14 2009-12-30 Новартис Аг Композиции и способы, предназначенные для лечения мышечных и сердечно-сосудистых нарушений
WO2008074328A2 (en) 2006-12-21 2008-06-26 Exiqon A/S Microrna target site blocking oligos and uses thereof
EP3536788A1 (en) 2006-12-21 2019-09-11 QIAGEN GmbH Microrna target site blocking oligos and uses thereof
WO2008113832A2 (en) 2007-03-22 2008-09-25 Santaris Pharma A/S SHORT RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF TARGET mRNA
WO2008131191A2 (en) 2007-04-20 2008-10-30 Amgen Inc. Nucleic acids hybridizable to micro rna and precursors thereof
WO2008147837A1 (en) 2007-05-23 2008-12-04 Dharmacon, Inc. Micro-rna scaffolds, non-naturally occurring micro-rnas, and methods for optimizing non-naturally occurring micro-rnas
CN101808649B (zh) 2007-07-31 2014-05-21 得克萨斯系统大学董事会 控制肌球蛋白表达和肌纤维身份的微小rna
US20100292099A1 (en) 2007-08-23 2010-11-18 Keren Pharmaceutical, Inc. Targeting of rna with external guide sequences
EP3112464A1 (en) 2007-09-14 2017-01-04 The Ohio State University Research Foundation Mirna expression in human peripheral blood microvesicles and uses thereof
AU2008306327B2 (en) 2007-10-04 2014-05-15 Roche Innovation Center Copenhagen A/S Micromirs
WO2009058818A2 (en) 2007-10-29 2009-05-07 The Board Of Regents Of The University Of Texas System Compositions comprising a micro-rna and methods of their use in regulating cardiac remodeling
DE102007052114B4 (de) 2007-10-30 2011-01-05 T2Cure Gmbh Verfahren zur Modulation der Funktion, des Wachstums oder der Differenzierung einer Zelle
CN101424640B (zh) 2007-11-02 2012-07-25 江苏命码生物科技有限公司 血清中微小核糖核酸的检测方法和用于检测的试剂盒、生物芯片及其制作和应用方法
JP5654352B2 (ja) 2007-11-09 2015-01-14 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム ｍｉＲ−１５ファミリーのマイクロＲＮＡによる心筋細胞生存及び心臓修復の調節
US8404658B2 (en) 2007-12-31 2013-03-26 Nanocor Therapeutics, Inc. RNA interference for the treatment of heart failure
EP2096171A1 (en) 2008-02-27 2009-09-02 Julius-Maximilians-Universität Würzburg MicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes
US8404659B2 (en) 2008-03-07 2013-03-26 Santaris Pharma A/S Pharmaceutical compositions for treatment of MicroRNA related diseases
WO2009114681A2 (en) 2008-03-13 2009-09-17 Dharmacon, Inc. Identification of mirna profiles that are diagnostic of hypertrophic cardiomyopathy
US20090326049A1 (en) 2008-04-04 2009-12-31 Alexander Aristarkhov Blocking oligos for inhibition of microrna and sirna activity and uses thereof
EP2297322A1 (en) 2008-06-04 2011-03-23 The Board of Regents of The University of Texas System Modulation of gene expression through endogenous small rna targeting of gene promoters
WO2009151600A2 (en) 2008-06-10 2009-12-17 Tufts University Smad proteins control drosha-mediated mirna maturation
EP2310505B1 (en) * 2008-06-30 2017-08-09 Roche Innovation Center Copenhagen A/S Antidote oligomers
CN101386848A (zh) 2008-08-12 2009-03-18 南京大学 细胞微粒子所载微小核糖核酸及其制备研究方法和应用
US8691971B2 (en) 2008-09-23 2014-04-08 Scott G. Petersen Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating RNA interference
US8987435B2 (en) 2008-10-24 2015-03-24 Isis Pharmaceuticals, Inc. Oligomeric compounds and methods
CA2751489A1 (en) 2009-02-04 2010-08-12 Board Of Regents, The University Of Texas System Dual targeting of mir-208 and mir-499 in the treatment of cardiac disorders
WO2010093788A2 (en) 2009-02-11 2010-08-19 Dicerna Pharmaceuticals, Inc. Multiplex dicer substrate rna interference molecules having joining sequences
WO2010122538A1 (en) * 2009-04-24 2010-10-28 Santaris Pharma A/S Pharmaceutical compositions for treatment of hcv patients that are non-responders to interferon
EP2427472B1 (en) 2009-05-05 2016-06-22 Miragen Therapeutics Lipophilic polynucleotide conjugates
US20120148664A1 (en) 2009-06-08 2012-06-14 Miragen Therapeutics Chemical modifications motifs for mirna inhibitors and mimetics
US9078914B2 (en) 2009-09-10 2015-07-14 Velin-Pharma A/S Method for the preparation of micro-RNA and its therapeutic application
US9364495B2 (en) 2009-10-20 2016-06-14 Roche Innovation Center Copenhagen A/S Oral delivery of therapeutically effective LNA oligonucleotides
US8592151B2 (en) 2009-11-17 2013-11-26 Musc Foundation For Research Development Assessing left ventricular remodeling via temporal detection and measurement of microRNA in body fluids
US20130109738A1 (en) 2010-02-24 2013-05-02 The Board Of Trustees Of The Leland Stanford Junior University Control of Cardiac Growth, Differentiation and Hypertrophy
EP2550360B1 (en) 2010-03-24 2017-08-30 Mirrx Therapeutics A/s Bivalent antisense oligonucleotides
US9821009B2 (en) 2010-04-13 2017-11-21 Jiangsu Mingma Biotech Co., Ltd. Method for modulating microRNA content in living beings and the use thereof
EP3124623B1 (en) 2010-04-20 2018-03-28 Hummingbird Diagnostics GmbH Complex mirna sets as novel biomarkers for an acute coronary syndrome
WO2011139911A2 (en) 2010-04-29 2011-11-10 Isis Pharmaceuticals, Inc. Lipid formulated single stranded rna
US20130150256A1 (en) 2010-06-11 2013-06-13 Jane Synnergren Novel micrornas for the detection and isolation of human embryonic stem cell-derived cardiac cell types
ITMI20101089A1 (it) 2010-06-16 2011-12-17 Istituto Naz Di Genetica Molecolare Ingm Profili di espressione di micro-rna nel sangue periferico per il monitoraggio del sistema immunitario
US9987309B2 (en) 2010-07-08 2018-06-05 Duke University Direct reprogramming of cells to cardiac myocyte fate
GB201012418D0 (en) * 2010-07-23 2010-09-08 Santaris Pharma As Process
WO2012018866A2 (en) 2010-08-03 2012-02-09 University Of South Alabama Methods and compositions for the diagnosis and treatment of breast cancer
AU2011288262A1 (en) 2010-08-13 2013-04-04 The University Court Of The University Of Glasgow Therapeutic uses of microvesicles and related microRNAs
KR20130137160A (ko) 2010-08-24 2013-12-16 머크 샤프 앤드 돔 코포레이션 내부의 비－핵산 스페이서를 함유하는 단일－가닥 ＲＮＡｉ 작용제
EP2616543A1 (en) 2010-09-15 2013-07-24 Alnylam Pharmaceuticals, Inc. MODIFIED iRNA AGENTS
JP5995855B2 (ja) * 2010-11-05 2016-09-21 ミラゲン セラピューティクス，インコーポレイテッド 塩基修飾オリゴヌクレオチド
CA2817371A1 (en) * 2010-12-15 2012-06-21 Miragen Therapeutics Microrna inhibitors comprising locked nucleotides
WO2012149646A1 (en) 2011-05-05 2012-11-08 Sunnybrook Research Institute Mirna inhibitors and their uses
US9428749B2 (en) 2011-10-06 2016-08-30 The Board Of Regents, The University Of Texas System Control of whole body energy homeostasis by microRNA regulation
GB201117482D0 (en) 2011-10-11 2011-11-23 Univ Dundee Targetiing of miRNA precursors
EP2584040A1 (en) 2011-10-17 2013-04-24 Pharmahungary 2000 Kft. Compounds for treatment of ischemic injury
CA2852917C (en) 2011-10-18 2020-07-07 Dicerna Pharmaceuticals, Inc. Amine cationic lipids and uses thereof
CA2895077A1 (en) 2011-12-12 2013-06-20 Beverly Packard In vivo delivery of oligonucleotides
WO2013088338A1 (en) 2011-12-15 2013-06-20 Oncostamen S.R.L. Micrornas and uses therof
EP2604690A1 (en) 2011-12-15 2013-06-19 Oncostamen S.r.l. MicroRNAs and uses thereof
FR2984358A1 (fr) 2011-12-16 2013-06-21 Genethon Methodes pour le diagnostic de dystrophies musculaires
CN104685056A (zh) 2012-06-21 2015-06-03 米拉根医疗股份有限公司 包含锁核酸基序的基于寡核苷酸的抑制剂
US9163235B2 (en) 2012-06-21 2015-10-20 MiRagen Therapeutics, Inc. Inhibitors of the miR-15 family of micro-RNAs
EP2759595B1 (en) 2013-01-24 2016-09-14 Pierre Fabre Médicament S.A.S. Composition comprising an encapsulated antagomir
HK1249108A1 (zh) 2015-01-20 2018-10-26 米拉根医疗股份有限公司 Mir-92抑制剂及其用途

Also Published As

Publication number Publication date
MX2014015643A (es) 2015-07-17
EP2864482A2 (en) 2015-04-29
DK3354734T3 (da) 2020-06-29
JP6208228B2 (ja) 2017-10-04
KR101928418B1 (ko) 2018-12-12
US10337005B2 (en) 2019-07-02
CA2876180C (en) 2019-11-19
US9803202B2 (en) 2017-10-31
AU2013278011A1 (en) 2015-01-15
CN104685056A (zh) 2015-06-03
AU2013278011B2 (en) 2018-09-20
US20160326526A1 (en) 2016-11-10
ES2801875T3 (es) 2021-01-14
WO2013192576A3 (en) 2014-04-03
EP3354734A1 (en) 2018-08-01
EP2864482A4 (en) 2016-02-10
US20130344135A1 (en) 2013-12-26
HK1209781A1 (en) 2016-04-08
KR20150023687A (ko) 2015-03-05
CN107236735B (zh) 2019-11-08
WO2013192576A2 (en) 2013-12-27
HK1244509A1 (zh) 2018-08-10
EP3354734B1 (en) 2020-06-10
CN107236735A (zh) 2017-10-10
US20180273944A1 (en) 2018-09-27
CA2876180A1 (en) 2013-12-27
US9388408B2 (en) 2016-07-12
JP2017217007A (ja) 2017-12-14
JP2015521626A (ja) 2015-07-30

Similar Documents

Publication Publication Date Title
MX355408B (es) Inhibidores a base de oligonucleotidos que comprenden un motivo de acido nucleico bloqueado.
MX2021015290A (es) Composiciones y metodos para inhibicion de genes para apolipoproteina c-iii (apoc3).
MX2013005875A (es) Inhibidores de microarn que comprenden nucleotidos bloqueados.
HRP20210612T1 (hr) Postupci i pripravci za specifičnu inhibiciju glikolat oksidaze (hao1) pomoću dvolančane rnk
MX2013009191A (es) Oligonucleotidos antisentido.
MD20150006A2 (ro) Inhibitori de micro-ARN din familia miR-15
NZ593618A (en) Gnaq targeted dsrna compositions and methods for inhibiting expression
MX2018013216A (es) Composiciones y metodos para inhibir la expresion del gen de proteasa transmembrana, serina 6 (tmprss6).
MX2024005653A (es) Agentes de acido ribonucleico (arn) de cadena doble modificados.
EA200870402A1 (ru) Фармацевтическая композиция
WO2014154835A3 (en) Modified tgf-beta oligonucleotides
EA201100813A1 (ru) Фармацевтическая композиция
WO2009014887A3 (en) Stabilized immune modulatory rna (simra) compounds
NZ592867A (en) Compositions and methods for inhibiting expression of transthyretin
MX2010004452A (es) Acido ribonucleico de doble cadena modificado con lipidos que tienen un potente efecto de interferencia de acido ribonucleico.
MX2011013176A (es) Motivos de modificación química para inhibidores y miméticos del miarn.
WO2009111658A3 (en) Compositions and methods for inhibiting expression of eg5 and vegf genes
WO2011008730A3 (en) Chemical modification of small hairpin rnas for inhibition of gene expression
WO2010003420A3 (en) Treatment of psoriasis and related diseases by mirna modulation
IN2014CN03921A (es)
HK1199285A1 (en) Compositions and methods for inducing apoptosis
WO2011054939A3 (en) Compositions and methods for inhibiting expression of kif10 genes
WO2011065677A3 (ko) 암 치료용 약학 조성물
NZ728207A (en) Oligonucleotide-based inhibitors comprising locked nucleic acid motif
JP2018520150A5 (es)

Legal Events

Date Code Title Description
FG Grant or registration